In ALL, BET inhibitors have shown efficacy in arresting growth of MLL-AF4+ leukaemic cells and in combination with imatinib in NUP214-ABL1/TLX3-expressing T-ALL cells [125,126]. This evidence concerns the gene NUP214 and acute lymphoblastic leukemia.